Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Greenspan

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
BMC Psychiatry|October 24, 2006
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trialGeorges M Gharabawi, Andrew Greenspan, Marcia F T Rupnow, et al.
Schizophrenia Research|August 25, 2006
A model of anticholinergic activity of atypical antipsychotic medicationsMarci L Chew, Benoit H Mulsant, Bruce G Pollock, et al.
Annals of the Rheumatic Diseases|January 15, 2017
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexateJosef S Smolen, Sandeep K Agarwal, Elena Ilivanova, et al.
Epilepsia|October 30, 2009
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trialsMichael R Sperling, Andrew Greenspan, Joyce A Cramer, et al.
Investigational New Drugs|October 13, 2010
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete responseRobert M Rifkin, Andrew Greenspan, John F Schwerkoske, et al.
The Journal of Rheumatology|August 3, 2015
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug TherapyMark C Genovese, Elizabeth Hsia, Stanley M Belkowski, et al.
Journal of the American Geriatrics Society|May 31, 2008
Anticholinergic activity of 107 medications commonly used by older adultsMarci L Chew, Benoit H Mulsant, Bruce G Pollock, et al.
The Journal of Dermatology|December 11, 2014
Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitisYoko Murata, Michael Song, Hisayuki Kikuchi, et al.
Journal of Psychiatric Research|February 26, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophreniaMarilyn Ader, W Timothy Garvey, Lawrence S Phillips, et al.
The Journal of Rheumatology|July 17, 2016
Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II StudiesRobin L Thurmond, Andrew Greenspan, Waldemar Radziszewski, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
BMC Psychiatry|October 24, 2006
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trialGeorges M Gharabawi, Andrew Greenspan, Marcia F T Rupnow, et al.
Schizophrenia Research|August 25, 2006
A model of anticholinergic activity of atypical antipsychotic medicationsMarci L Chew, Benoit H Mulsant, Bruce G Pollock, et al.
Annals of the Rheumatic Diseases|January 15, 2017
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexateJosef S Smolen, Sandeep K Agarwal, Elena Ilivanova, et al.
Epilepsia|October 30, 2009
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trialsMichael R Sperling, Andrew Greenspan, Joyce A Cramer, et al.
Investigational New Drugs|October 13, 2010
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete responseRobert M Rifkin, Andrew Greenspan, John F Schwerkoske, et al.
The Journal of Rheumatology|August 3, 2015
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug TherapyMark C Genovese, Elizabeth Hsia, Stanley M Belkowski, et al.
Journal of the American Geriatrics Society|May 31, 2008
Anticholinergic activity of 107 medications commonly used by older adultsMarci L Chew, Benoit H Mulsant, Bruce G Pollock, et al.
The Journal of Dermatology|December 11, 2014
Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitisYoko Murata, Michael Song, Hisayuki Kikuchi, et al.
Journal of Psychiatric Research|February 26, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophreniaMarilyn Ader, W Timothy Garvey, Lawrence S Phillips, et al.
The Journal of Rheumatology|July 17, 2016
Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II StudiesRobin L Thurmond, Andrew Greenspan, Waldemar Radziszewski, et al.
Pageof 4